Chemotherapy-Induced Hematological Toxicity in Patients with Renal or Hepatic Impairment

<b>Background/Objectives</b>: Hematological toxicities (i.e., neutropenia, thrombocytopenia, and anemia), are common chemotherapy complications and may be exacerbated by renal or hepatic impairment due to altered drug exposure. This study assessed the association between renal and hepatic impairment and hematologic toxicities during chemotherapy in routine clinical practice. <b>Methods</b>: A single-center retrospective cohort study using the Utrecht Patient Oriented Database (UPOD) identified all chemotherapy administrations at the University Medical Centre Utrecht between 2011 and 2024. Regimens administered in ≥10 patients and ≥5 renally (GFR < 60 mL/min) or hepatically (bilirubin or AST > 1× ULN) impaired patients were included in descriptive analyses. Cox proportional hazards models estimated associations between organ impairment and grade ≥ 3 hematologic toxicities for regimens with ≥10 events per toxicity endpoint. <b>Results</b>: Overall, 4489 patients were included in renal analyses and 6218 in hepatic analyses, with smaller endpoint-specific subgroups for survival analyses. Renal impairment was associated with grade ≥ 3 neutropenia (HR: 1.43 [95% CI: 1.18-1.73]), thrombocytopenia (HR: 1.46 [95% CI: 1.15-1.86], and anemia (HR: 1.66 [1.27-2.16]). Hepatic impairment was similarly associated with neutropenia (HR: 1.25 [95% CI: 1.11-1.40]), thrombocytopenia (HR: 1.33 [95% CI: 1.13-1.57]), and anemia (HR: 1.62 [95% CI: 1.34-1.95]). Cyclophosphamide (pro-drug) regimens showed higher toxicity risk in renally impaired patients and reduced risk in hepatically impaired patients. Etoposide, melphalan and methotrexate were associated with increased toxicity in hepatically impaired patients. <b>Conclusions</b>: Renal and hepatic impairment significantly increase chemotherapy-induced hematologic toxicity. Several high-risk chemotherapy regimens were identified; however, larger multi-center datasets are needed to refine dosing guidance based on renal and hepatic function.

Authors

Institutions

Publication Details

Journal
Pharmaceutics
Published
2025-09-30
DOI
https://doi.org/10.3390/pharmaceutics17101280
Primary Topic
Chemotherapy-induced organ toxicity mitigation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Chemotherapy-Induced Hematological Toxicity in Patients with Renal or Hepatic Impairment

Laureen A. Lammers, Saskia Haitjema, Robin W.M. Vernooij, Jan‐Hendrik Venhuizen et al.
Pharmaceutics
Chemotherapy-induced organ toxicity mitigation
article

Chemotherapy-Induced Hematological Toxicity in Patients with Renal or Hepatic Impairment

Laureen A. Lammers, Saskia Haitjema, Robin W.M. Vernooij, Jan‐Hendrik Venhuizen, Kelly Nies, Lot A. Devriese, Maarten J. ten Berg, Christina Swart
article en

Abstract

<b>Background/Objectives</b>: Hematological toxicities (i.e., neutropenia, thrombocytopenia, and anemia), are common chemotherapy complications and may be exacerbated by renal or hepatic impairment due to altered drug exposure. This study assessed the association between renal and hepatic impairment and hematologic toxicities during chemotherapy in routine clinical practice. <b>Methods</b>: A single-center retrospective cohort study using the Utrecht Patient Oriented Database (UPOD) identified all chemotherapy administrations at the University Medical Centre Utrecht between 2011 and 2024. Regimens administered in ≥10 patients and ≥5 renally (GFR < 60 mL/min) or hepatically (bilirubin or AST > 1× ULN) impaired patients were included in descriptive analyses. Cox proportional hazards models estimated associations between organ impairment and grade ≥ 3 hematologic toxicities for regimens with ≥10 events per toxicity endpoint. <b>Results</b>: Overall, 4489 patients were included in renal analyses and 6218 in hepatic analyses, with smaller endpoint-specific subgroups for survival analyses. Renal impairment was associated with grade ≥ 3 neutropenia (HR: 1.43 [95% CI: 1.18-1.73]), thrombocytopenia (HR: 1.46 [95% CI: 1.15-1.86], and anemia (HR: 1.66 [1.27-2.16]). Hepatic impairment was similarly associated with neutropenia (HR: 1.25 [95% CI: 1.11-1.40]), thrombocytopenia (HR: 1.33 [95% CI: 1.13-1.57]), and anemia (HR: 1.62 [95% CI: 1.34-1.95]). Cyclophosphamide (pro-drug) regimens showed higher toxicity risk in renally impaired patients and reduced risk in hepatically impaired patients. Etoposide, melphalan and methotrexate were associated with increased toxicity in hepatically impaired patients. <b>Conclusions</b>: Renal and hepatic impairment significantly increase chemotherapy-induced hematologic toxicity. Several high-risk chemotherapy regimens were identified; however, larger multi-center datasets are needed to refine dosing guidance based on renal and hepatic function.

PharmaceuticsVol. 17(10)
Utrecht University (NL), University Medical Center Utrecht (NL)
Health~Holland, Universitair Medisch Centrum Utrecht
Openalex Percentile: Top 62%
Chemotherapy-induced organ toxicity mitigation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.